Jane S. Vergnes, Ph.D., DABT®

Vice President, Scientific Affairs and Director of Toxicology


Vice President, Scientific Affairs and Director of Toxicology for The Acta Group (Acta®), Dr. Vergnes provides clients with toxicology, product stewardship, and regulatory expertise for the broad range of chemical regulatory and support services Acta offers, including support for Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) dossiers in the European Union and the United Kingdom, Toxic Substances Control Act (TSCA) new and existing chemicals reviews, California Proposition 65 (Prop 65) initiatives, pesticide risk assessments, and hazard communication. A leader with more than 30 years of experience in global product stewardship, she offers clients an agile, multi-disciplinary talent for problem-solving honed during her years directing product stewardship and toxicology programs for Ashland, Inc., International Specialty Products (ISP), Texaco, and Union Carbide (now Dow). Dr. Vergnes is also an experienced research scientist and scientific study director with a Ph.D. in Human Genetics and a specialization in the genetic/epigenetic modes of action of toxicants, and she deploys the full depth of her scientific, business, and policy knowledge to resolve clients’ challenges.

Representative Engagements

  • Assisted a U.S. company with development of an approach to compliance with the Conflict Minerals provisions of Dodd–Frank.
  • Provided technical support to an international client through the Integrated Risk Information System (IRIS) public meeting process.
  • Aided a multinational client with development of a surrogate No Significant Risk Level under California Proposition 65.
  • Helped several clients address various regulatory compliance and safety issues for chemicals regulated under food, drug, and cosmetics regulations

Articles and Writings

  • L. Bergeson, B. Auerbach, L. Campbell, T. Backstrom, S. Dolan, J. Vergnes, R. Engler, J. Bultena, K. Baron, C. Auer, “The DNA of the U.S. Regulatory System: Are We Getting It Right for Synthetic Biology?,” Woodrow Wilson International Center for Scholars Synthetic Biology Project Report, October 15, 2015.

  • Bevan, C., Gargas, M., Kirman, C., and Vergnes, J.  2009.  “Mode of Action and Derivation of a Cancer and Non-cancer Reference Value for 4-Vinylcyclohexene.” Toxicologist 108(1)

  • Vergnes, J.S. and Ballantyne, B.  2002.  “Genetic Toxicology Studies with Glutaraldehyde.”  J. Appl. Toxicol. 22:45-60.

  • Vergnes, J.S. and Ballantyne, B.  2001.  “In Vitro and in Vivo Genetic Toxicology Studies with Diethylene Glycol Monohexyl Ether.”  J. Appl. Toxicol. 21: 449-460.

B&C, Acta, and BCCM provide a full range of global support for the commercialisation of chemicals, biocides, and products of industrial biotechnology, nanotechnology, and synthetic biology.

View Our Services


  • BA, Ohio Wesleyan University, Bacteriology, 1974
  • Ph.D., University of Pittsburgh, Human Genetics, 1982

Rankings & Recognition

  • Diplomate of the American Board of Toxicology